---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-25-010830"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:30:26.749132+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro FY2025 cash $3.9M, equity $3.9M; $5M financing completed ahead of schedule

## Summary
- Cash of $3.9M at April 30, 2025 vs $0.4M prior year; stockholder equity of $3.9M vs deficit $2.6M.
- Net cash from financing activities was $10.4M for FY2025.
- Completed $5M private placement in June 2025, months early; investor accelerated purchase of additional $4M preferred stock.
- Dosed first patient in May 2025 for AL001 'Lithium in Brain' Phase II studies at Mass General; topline results expected year-end 2025.
- ALZN002 immunotherapy trial delayed; actively seeking new CRO after prior CRO terminated in Feb 2024.

## SEC filing metadata
- accession: 0001214659-25-010830
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/0001214659-25-010830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/i7232518k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-25-010830
- JSON: https://secwatch.observer/filing/0001214659-25-010830.json
- Plain text: https://secwatch.observer/filing/0001214659-25-010830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.